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recent recommendations for epilepsy care in the elderly.
Research is needed to identify why new patients receive
phenobarbital. The vast use of phenytoin suggests
research evaluating the impact of phenytoin and other
AEDs on the elderly in actual practice may be needed to
facilitate adoption of recent clinical recommendations.
EMPLOYER PERSPECTIVES
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OBJECTIVES: Allergies and many sedating over-the-
counter (OTC) allergy medications have been shown to
have a signiﬁcant and negative impact on lost productive
time at work. We examine the impact of an allergy
program designed to reduce sedating allergy medication
use and its impact on employee-reported lost productiv-
ity within a large southern California medical group.
METHODS: A baseline questionnaire designed to
measure allergy symptoms, severity, treatment strategies,
and disease burden was distributed to 712 employees in
November 2001 with a follow-up questionnaire sent in
November 2002. We calculated change in self-reported
productive time lost due to allergy related full and partial
missed days, and presenteeism (lower productive time
while at work) from merged baseline and follow-up data.
Interventions included recommended treatment guide-
lines that were developed and distributed to all physicians
and clinics. Employees were encouraged to discuss their
allergy medications and treatment strategies with their
physicians and were provided access to a corporate
Intranet site for additional allergy-speciﬁc information.
RESULTS: Response rates of 85% and 58% were
achieved at baseline and 1-year follow-up. In addition,
59% of allergic employees participated in the program
with 44% reporting visiting a doctor and 28% using the
Intranet. Sedating OTC medication use dropped from
38% to 21% (p < .0001). Allergy speciﬁc average
monthly hours missed decreased due to presenteeism (7.2
hours; p < .0001) and overall (5.5 hours; p = .0076) per
allergic employee. Average monthly hours missed
increased due to full days (1.1 hour) and partial days (.06
hour) but were not statistically signiﬁcant. CONCLU-
SIONS: While allergies account for a signiﬁcant number
of lost productive work hours, an allergy program can
successfully reduce sedating medication use, consequent
disease burden, and lost productive work time. Projected
annually, appropriate treatment of allergy symptoms
resulted in cost savings of approximately $1254 per aller-
gic employee.
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OBJECTIVE: With improvements in therapy, HCV
disease progression can be better controlled and a greater
number of infected patients are able to remain in the
workforce. This analysis quantiﬁes the incremental direct
(medical, drugs) and indirect (absenteeism, disability)
costs of HCV from an employer’s perspective.
METHODS: Based on eligibility, medical, pharmacy and
disability claims data from seven major US employers
covering January 1, 1998 through June 30, 2001, we
identiﬁed 833 HCV infected patients having at least 2
claims with a HCV ICD-9 diagnosis code less than 90
days apart, ribavirin and interferon combination therapy,
a conﬁrmatory HCV lab test followed by a HCV diag-
nosis, or a HCV diagnosis coupled with non-alcoholic 
cirrhosis, hepatocarcinoma, liver transplantation, or
cryoglobulinemia. A 10% random sample of 148,166
uninfected individuals was chosen as controls. Employer
costs resulted from direct medical costs and employee
productivity loss. A tobit regression, which corrects for
non-normality of costs, included controls for age, gender,
health plan, location, alcohol abuse, HIV status, and
illicit drug use. RESULTS: The unadjusted ratio of mean
direct costs for HCV infected patients compared to unin-
fected patients was 7.9 :1 ($857.4 vs. $108.1 per patient-
month, p < .01). The ratio for indirect costs was 4.0 :1
($88.7 vs. $22.3 per patient-month, p < .01). After con-
trolling for confounding factors, the ratios were 5.6 :1
(95% CI: 5.6–5.7) for direct costs, and 8.1:1 (95% CI:
7.9–8.4) for indirect costs. Regressions on sub-categories
yielded costs ratios for inpatient care, outpatient care,
prescription drugs, absenteeism, and disability (short 
and long-term) of 5.3 :1 (95% CI: 5.2–5.4), 5.0:1 (95%
CI: 5.0–5.1), 7.5:1 (95% CI: 7.4–7.5), 5.5:1 (95% 
CI: 5.4–5.7), and 10.0 :1 (95% CI: 9.2–10.8), respec-
tively. CONCLUSION: Both the unadjusted and adjusted
cost ratios for HCV infected patients compared to unin-
fected patients indicate that infection results in statisti-
cally signiﬁcant increases in both direct and indirect costs
to the employers.
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OBJECTIVE: Chronic non-cancer pain (CNCP) is a 
condition that may result in high healthcare costs 
and reduced workplace productivity. The objective of 
this study was to quantify work loss and pain-related
healthcare utilization among employees with CNCP.
METHODS: A retrospective analysis was conducted
using the MEDSTAT Health and Productivity Manage-
ment database, which includes absences, worker’s com-
pensation and short-term disability claims for employees
from six large U.S. corporations along with inpatient,
outpatient, and pharmacy claims from 1997–1999. Pres-
ence of CNCP was deﬁned as 90+ days supply of opioids
within the study period and a pain-related diagnosis.
Workdays lost (absences plus short-term disability) were
converted to dollars ($US1998) using location-speciﬁc
wage rates from the US Bureau of Labor Statistics.
Healthcare utilization included opioid usage, pain-related
outpatient medical visits, and pain-related inpatient 
hospitalizations. RESULTS: From the original outpatient
data ﬁle of 236,736 employees, 2,459 had CNCP and
were eligible to have work loss data reported, of which
1,512 experienced sickness absence(s) and/or short-term
disability days. Those with work loss experienced a
longer median duration of pain than those without work
loss (887 vs. 934.5 days). Pain-related direct costs were
$5378 per employee per year. Indirect costs (wages lost
per employee per year) were $5339–$7475, based on sen-
sitivity analyses. The total impact of CNCP for employ-
ees whose work loss was recorded was at least $2.1
million per employer per year. CONCLUSIONS: Few
data have been compiled to examine the economic impact
of CNCP speciﬁcally to employers. The ﬁndings demon-
strate that CNCP is associated with signiﬁcant resource
consumption and lost workdays, and suggest a need for
employer-sponsored pain management programs.
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OBJECTIVES: This analysis quantiﬁes the prevalence,
health beneﬁts cost, and real productivity loss experi-
enced by employees as a result of allergies. Healthcare
claims and employee population data are used to quan-
tify the prevalence of respiratory system allergies. Addi-
tionally, demographic, health beneﬁts, and output-based
productivity data are used to compare the health beneﬁts
cost and productivity of employees with and without
allergies. METHODS: Using data from October 2000 to
September 2002, this study examines 86,000 geographi-
cally-disperse employees. An employee was deﬁned to
have an allergy diagnosis if the employee had a health-
care claim with a primary ICD9 code of 477.xx or
493.0x. Logistic regression was used to determine the
demographic factors that were associated with the 
likelihood of ﬁling an allergy claim. In addition, tobit 
and linear regression models were used to determine the
isolated impact of an allergy diagnosis on an employee’s
health beneﬁts cost and productivity output. RESULTS:
Of the employee population examined, 17.3% were diag-
nosed with allergies during the 2-year period. An allergy
diagnosis was associated with a subsequent isolated
increase of $106 per month (p < 0.001) in the employee’s
total beneﬁts cost (including healthcare, prescription
drug, sick leave, short- and long-term disability, and
workers’ compensation). Similarly, an allergy diagnosis
was associated with a subsequent isolated decrease in pro-
ductivity (units processed per hour) of 2.7% (p < 0.001).
CONCLUSIONS: Nearly one in six employees were diag-
nosed with allergies during the study period, resulting in
signiﬁcantly higher costs to the employer and signiﬁcantly
lower productivity. Employers will use this information
to more accurately assess the beneﬁts of supporting 
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OBJECTIVES: Recently reported rates of Medicare ben-
eﬁciaries restricting prescription medication use because
of cost ranges from 1.6 to 22%. A reliable estimate of
prescription non-procurement due to cost and an under-
standing of this behavior is essential to appropriate policy
development. METHODS: The 2000 Health and 
Retirement Study, nationally representative of Americans
born before 1947, provides cross-sectional data regard-
ing respondent insurance coverage and prescription 
non-procurement. All non-institutionalized, Medicare
beneﬁciaries age 65 and older were identiﬁed. Weighted
bivariate analysis and multivariate stepwise logistic
regression modeling determined the association and inde-
pendent predictive value of several risk factors, including
total health insurance coverage, on prescription non-
procurement. RESULTS: Data for 9771 respondents were
identiﬁed. Prescription non-procurement due to cost was
reported in 4.5%, 8.5%, and 9.8% of respondents with
Medicare plus private insurance, Medicare only, and
Medicare plus Medicaid, respectively. Bivariate analysis
revealed similar risk factor-related trends both within and
between health insurance categories. The ﬁnal regression
model included several signiﬁcant factors (p < 0.0001)
predictive of non-procurement, the most notable being
income, number of symptoms, and total prescription
